Abstract
A short and efficient synthesis of three stereoisomeric and three process impurities of Alalevonadifloxacin mesylate (WCK 2349), a novel anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic, has been disclosed. The synthesis and characterization of these impurities are discussed in detail to provide access to the reference standards for the impurity profile of the drug substance as well as the drug product. Moreover, systematic analytical method development for stereospecific separation between alalevonadifloxacin mesylate (1) and an enantiomer, WCK 6577 (2) in the presence of other process impurities for accurate quantification using liquid chromatography is also discussed.